AI-based drug screening uses machine learning and deep learning to analyze chemical structures, predict biological activity, and prioritize compounds for testing. Techniques include virtual screening, enhanced molecular docking, and predictive models for efficacy, safety, and ADMET properties. This accelerates lead identification, reduces costs, and improves success rates by narrowing candidates before laboratory and animal studies.

Yes. AI can help detect cancer by analyzing medical images such as X-rays, CT and MRI, as well as pathology slides and clinical data to identify suspicious patterns, improve early detection and prioritize cases. It can increase accuracy and speed but does not replace clinicians; clinical validation, regulatory approval and oversight are required because performance varies and may be affected by dataset quality and bias.

Do you mean "AI" as adenocarcinoma in situ of the cervix (often abbreviated AIS) or "AI" as artificial intelligence used in cervical screening/diagnosis?

AI stands for artificial intelligence in oncology. It denotes computer-based systems and algorithms, especially machine learning and deep learning, that analyze medical images, pathology, genomic and electronic health record data to assist cancer detection, diagnosis, risk prediction, treatment planning, and drug discovery. AI augments clinicians by improving accuracy, efficiency, and personalization but requires rigorous validation, regulatory approval, and ongoing oversight.

AI-based screening uses machine learning and computer vision to analyze medical data—such as imaging, lab results, and electronic health records—to detect patterns, flag abnormalities, and estimate risk. It assists clinicians by improving early detection, triage, and diagnostic accuracy, speeding workflows and reducing workload. AI screening requires clinical validation, oversight, and regulatory approval and is intended to support, not replace, healthcare professionals.

AI in endoscopy provides real-time lesion detection and characterization—flagging polyps during colonoscopy and distinguishing adenomas from benign lesions—reducing miss rates. It supports quality improvement by tracking procedural metrics, assists capsule endoscopy image review, aids biopsy decision-making, and streamlines reporting and training, improving diagnostic accuracy, consistency, and workflow efficiency.